Clinical trial NCT06656325: An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis
Official title: An Evaluation of the Effect of the Erchonia Corporation FX-405 Laser as an Adjunctive Treatment of Periodontitis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Periodontal Diseases
Periodontitis
Gum Disease
Lead sponsor: Erchonia Corporation
Sponsor class: INDUSTRY
First posted: 2024-10-24
Enrollment: 70
Sex: ALL
Minimum age (years): 22
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.

Detailed description: The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease. This clinical study is a double-blind design, such that neither the subject, nor the investigators - the investigator administering the treatment with the Erchonia® FX-405™ device (administration investigator) or the investigator recording the outcome measures (assessment investigator) - will be aware of whether the subject has been assigned to the active treatment test group or to the sham treatment control group until after the study is complete. All study subjects, regardless of treatment group assignment will receive active scaling and root planing standard of care therapy in addition to the active or sham therapy with the Erchonia® FX-405™ device.

Eligibility criteria: Inclusion Criteria:

* Subject has voluntarily signed a written informed consent form.
* Male or female 22 to 75 years of age, inclusive.
* Subject has no evidence of Localized Aggressive Periodontitis.
* Tooth loss due to periodontitis of ≤ 4 teeth.
* Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months
* Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.
* Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.
* Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.
* Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study

Exclusion Criteria:

* Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.
* History of oral cancer or HIV in the last 6 months
* Pregnant or intending to become pregnant in the next 8 months.
* Sensitivity to, or contraindication for, light therapy.
* Currently enrolled in a clinical study of an investigational drug or device.

Primary outcomes:
measure: Number of participants with a change in Clinical Attachment Loss of ≥-2mm at the primary tooth assessment site
timeFrame: Baseline and 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Thousand Oaks
country: United States
facility: 805 Dentistry
state: California
city: Acton
country: United States
facility: Acton Dental Associates
state: Massachusetts
Study officials:
References: